vimarsana.com

Latest Breaking News On - Osimertinib tagrisso - Page 1 : vimarsana.com

FDA Grants Osimertinib Priority Review for Patients With Unresectable, Stage III EGFR-Mutated Lung Cancer

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Osimertinib delays progression way more than hoped in EGFR -mutant lung cancer

CHICAGO — Osimertinib following chemoradiotherapy drastically improved PFS compared with placebo in patients with advanced EGFR-mutant non-small cell lung cancer in a randomized phase 3 trial.Blinded independent review and study investigators separately determined a greater than 80% risk reduction for those treated with the osimertinib-based regimen, according to results presented at ASCO

vimarsana © 2020. All Rights Reserved.